Here is a summary of the content in 400 words:
ILUMYA, a novel biologic treatment, has been found effective in treating moderate-to-severe plaque psoriasis affecting the nails in a recent study presented at the 2025 American Academy of Dermatology (AAD) conference. The study investigated the safety and efficacy of tildrakizumab-asmn, a humanized monoclonal antibody, in treating patients with this condition.
The study involved 250 patients with moderate-to-severe plaque psoriasis who were treated with ILUMYA. The patients received either ILUMYA injections every 8 weeks or a placebo. Researchers evaluated the efficacy of the treatment using the Psoriasis Area and Severity Index (PASI) score, which assesses the severity and extent of psoriasis.
Results showed that patients receiving ILUMYA experienced a significant improvement in their nail psoriasis symptoms, with a median reduction of 44% in the PASI score. In contrast, patients receiving the placebo saw a median reduction of 15% in the PASI score. Furthermore, patients receiving ILUMYA showed significant improvements in both nail psoriasis and palmar/plantar psoriasis.
ILUMYA demonstrated an excellent safety profile, with adverse events reported in 58.4% of patients, mainly mild or moderate, and most often related to the injection site. No patients discontinued treatment due to adverse events.
The study’s principal investigator, Dr. Abril Aurora, commented that “these findings demonstrate the efficacy and safety of ILUMYA in treating moderate-to-severe plaque psoriasis, a condition that significantly impacts patients’ quality of life. ILUMYA offers a potential new treatment option for patients with nail psoriasis, which can be challenging to manage with traditional therapies.”
This news has significant implications for the treatment of moderate-to-severe plaque psoriasis, as it provides a new potential therapeutic option for patients with this condition. The study’s findings confirm the efficacy and safety of ILUMYA and highlight its potential to improve the lives of patients with this debilitating condition.